Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease
NCT03921242 is an observational study sponsored by Weill Medical College of Cornell University. As of 18 Nov 2026, it is completed. It studies DPP-4 inhibitor, GLP1 receptor agonist, Metformin, SGLT2 inhibitor and 1 more drug in Diabetes Mellitus, Type 2 and Renal Insufficiency, Chronic. The registry lists an enrollment of 4,888 participants at 2 sites in 1 country. The registry lists a start date of 1 Aug 2019 and a primary completion date of 1 Aug 2023.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03921242 |
| Status | Completed |
| Study type | Observational study |
| Lead sponsor | Weill Medical College of Cornell University |
| Enrollment | 4,888 |
| Registered sites | 2 |
| Countries | 1 |
| Conditions | Diabetes Mellitus, Type 2 and Renal Insufficiency, Chronic |
| Drugs | DPP-4 inhibitor, GLP1 receptor agonist, Metformin, SGLT2 inhibitor and Sulfonylurea |
| Start | 1 Aug 2019 |
| Primary completion | 1 Aug 2023 |
| Study completion | 1 Aug 2023 |
| Last update posted | 9 Nov 2023 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Alvin Mushlin
Weill Cornell Medical College/Memorial Sloan Kettering Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of North Carolina
Chapel Hill
- Vanderbilt University Medical Center
Nashville
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03921242
Each answer restates registry values shown on this page.
What is NCT03921242?
NCT03921242 is an observational study sponsored by Weill Medical College of Cornell University. It studies DPP-4 inhibitor, GLP1 receptor agonist, Metformin, SGLT2 inhibitor and 1 more drug in Diabetes Mellitus, Type 2 and Renal Insufficiency, Chronic.
Who leads NCT03921242?
The registry names Alvin Mushlin (principal investigator, Weill Cornell Medical College/Memorial Sloan Kettering Cancer Center) as the overall official.
Where does NCT03921242 run?
The registry lists 2 sites in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03921242 study?
The registered drug and biological interventions are DPP-4 inhibitor, GLP1 receptor agonist, Metformin, SGLT2 inhibitor and Sulfonylurea.
When did NCT03921242 end?
The registry lists a primary completion date of 1 Aug 2023 and a study completion date of 1 Aug 2023. The sponsor last updated the record on 9 Nov 2023.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.